Evidence map›Paper›PMID 41158800›Full record

ArticleFrontiers in pediatrics2025

Comparison of interrupted and continuous modulator therapy in cystic fibrosis: a real life experience in Turkey.

Almala Pinar Ergenekon, Merve Selcuk, Gokcen Unal, Gamzegul Gozen Bayramoğlu, Cansu Altuntas, Mehmet Kose, Abdurrahman Erdem Basaran, Sinem Can Oksay, Salih Uytun, Sedat Oktem and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Almala Pinar ErgenekonDivision of Pediatric Pulmonology, Marmara University School of Medicine, Istanbul, Türkiye.
Merve SelcukDivision of Pediatric Pulmonology, Marmara University School of Medicine, Istanbul, Türkiye.
Gokcen UnalDivision of Pediatric Pulmonology, Necmettin Erbakan University, Konya, Türkiye.
Gamzegul Gozen BayramoğluDivision of Pediatric Pulmonology, Gazi University, Ankara, Türkiye.
Cansu AltuntasDivision of Pediatric Gastroenterology, Istinye University, Istanbul, Türkiye.
Mehmet KoseDivision of Pediatric Pulmonology, Erciyes University, Kayseri, Türkiye.
Abdurrahman Erdem BasaranDivision of Pediatric Pulmonology, Akdeniz University, Antalya, Türkiye.
Sinem Can OksayDivision of Pediatric Pulmonology, Medeniyet University, Istanbul, Türkiye.
Salih UytunDivision of Pediatric Pulmonology, Ankara Bilkent Şehir Hastanesi, Ankara, Türkiye.
Sedat OktemDivision of Pediatric Pulmonology, Medipol University, Istanbul, Türkiye.
Zeynep Seda UyanDivision of Pediatric Pulmonology, Koc University, Istanbul, Türkiye.
Yakup CanitezDivision of Pediatric Pulmonology, Bursa Uludag University, Bursa, Türkiye.
Esen DemirDivision of Pediatric Pulmonology, Ege University, Izmir, Türkiye.
Velat SenDivision of Pediatric Pulmonology, Dicle University, Diyarbakır, Türkiye.
Veysel KarakulakDivision of Pediatric Allergy, Cukurova University, Adana, Türkiye.
Ela Erdem EralpDivision of Pediatric Pulmonology, Marmara University School of Medicine, Istanbul, Türkiye.
Bulent KaradagDivision of Pediatric Pulmonology, Marmara University School of Medicine, Istanbul, Türkiye.
Fazilet KarakocDivision of Pediatric Pulmonology, Marmara University School of Medicine, Istanbul, Türkiye.
Sevgi PekcanDivision of Pediatric Pulmonology, Necmettin Erbakan University, Konya, Türkiye.
Tugba Sismanlar EyuboğluDivision of Pediatric Pulmonology, Gazi University, Ankara, Türkiye.
Erkan CakırDivision of Pediatric Pulmonology, Istinye University, Istanbul, Türkiye.
Yasemin GokdemirDivision of Pediatric Pulmonology, Marmara University School of Medicine, Istanbul, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Cystic fibrosis (CF) transmembrane conductance regulator protein (CFTR) modulators have significantly improved health outcomes in patients with cystic fibrosis (pwCF). However, in Turkey, access is limited due to lack of insurance coverage, and treatment is only granted in 3-month periods via court rulings. This study aimed to compare clinical outcomes between patients receiving continuous vs. intermittent modulator therapy. Methods: In this retrospective multicenter study, data from 229 CF patients across 14 centers in Turkey who received highly effective modulator therapy (HEMT) for at least six months were analyzed. Patients were grouped based on whether they received treatment continuously (Group 1) or with interruptions (Group 2). Changes in percent predicted forced expiratory volume in one second (ppFEV₁) and body mass index (BMI) were evaluated at baseline, 3 months, and 6 months. For Group 2, ppFEV₁ was also assessed during interruption periods. Results: Of the 229 patients, 38.4% received continuous treatment while 61.5% experienced treatment interruptions. Both groups showed significant improvements in ppFEV₁ over six months ( Conclusion: Short-term clinical outcomes in ppFEV₁ and BMI were similar between continuous and intermittent treatment. However, treatment interruptions may reduce cumulative benefits, potentially impacting long-term outcomes. Ensuring uninterrupted access to HEMT is essential, especially in low- and middle-income countries

Indexed as

body mass indexCFTR modulator drugsinterrupted modulator therapy in cystic fibrosispulmonary function testreimbursement of modulator therapy in cystic fibrosis

Identifiers

PMID41158800
PMCPMC12554574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.